MBVX - MabVax Therapeutics Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.53
+0.04 (+2.68%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.49
Open1.52
Bid1.23 x 300
Ask1.75 x 1000
Day's Range1.39 - 1.68
52 Week Range1.29 - 6.90
Volume64,963
Avg. Volume127,611
Market Cap13.712M
Beta2.67
PE Ratio (TTM)N/A
EPS (TTM)-10.52
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting
    PR Newswire4 days ago

    MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting

    - Interim results from Phase 1 clinical trial of MVT-1075, demonstrated a dosing strategy for the clinical translation of a radioimmunotherapy product for the treatment of patients with relapsed / refractory ...

  • MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements
    PR Newswire9 days ago

    MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements

    - No immediate effect on the Company's Nasdaq listing or the trading of its common stock - SAN DIEGO , April 13, 2018 /PRNewswire/ --  MabVax Therapeutics Holdings, Inc . (NASDAQ: MBVX), a clinical-stage ...

  • PR Newswire20 days ago

    MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones

    The Company also provided an update on its corporate progress, clinical status and anticipated milestones for Phase 1 clinical programs including the MVT-5873 clinical trial in combination with a standard of care chemotherapy as a first line therapy for patients newly diagnosed with pancreatic cancer, and the MVT-1075 radioimmunotherapy clinical trial for the treatment of pancreatic, colon and lung cancers. Announced positive interim results from the Company's ongoing Phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in patients newly diagnosed with pancreatic and other CA19-9 positive malignancies.

  • Why MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Ownership Structure Is Important
    Simply Wall St.last month

    Why MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Ownership Structure Is Important

    In this article, I will take a quick look at MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) recent ownership structure – an unconventional investing subject, but an important one. A company’s ownershipRead More...

  • MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting
    PR Newswirelast month

    MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting

    - Company to present interim results from the Phase 1 clinical trial of MVT-1075, a radioimmunotherapy product for the treatment of patients with relapsed / refractory pancreatic cancer - Company to present ...

  • With A -68.72% Earnings Drop, Did MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) Really Underperform?
    Simply Wall St.last month

    With A -68.72% Earnings Drop, Did MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) Really Underperform?

    In this article, I will take a look at MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) most recent earnings update (30 September 2017) and compare these latest figures against its performance overRead More...

  • MabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
    PR Newswire2 months ago

    MabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

    SAN DIEGO, March 6, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Capital Market notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) as a result of maintaining the $1.00 minimum closing bid price for at least ten trading days prior to the March 5, 2018 deadline for continued listing. The Company regained compliance with the minimum bid price maintenance requirement as a result of completing on February 16, 2018 its previously announced 1-for-3 reverse stock split. The Company previously received written notification from Nasdaq regarding its non-compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) and was afforded 180 calendar days, or until March 5, 2018, to regain compliance with Nasdaq Listing Rule 5550(a)(2).

  • MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers
    PR Newswire2 months ago

    MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers

    SAN DIEGO, Feb. 28, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today positive interim results from the initial cohort of the Phase 1 clinical trial evaluating the Company's new human antibody-based radioimmunotherapy ("RIT") product MVT-1075 for the treatment of pancreatic, colon and lung cancer.

  • PR Newswire2 months ago

    Lifshitz & Miller LLP Announces Investigation of A10 Networks, Inc., Aerohive Networks, Inc., Jacksonville Bancorp, Inc., Key Technology, Inc., MabVax Therapeutics Holdings, Inc., MetLife Inc. and Xerox Corporation

    NEW YORK , Feb. 19, 2018 /PRNewswire/ -- A10 Networks, Inc. (ATEN) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the Company's revenue ...

  • MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
    PR Newswire2 months ago

    MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

    SAN DIEGO , Feb. 15, 2018 /PRNewswire/ --  MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development ...

  • MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer
    PR Newswire2 months ago

    MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer

    SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today positive interim results from the Company's ongoing Phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in patients newly diagnosed with pancreatic and other CA19-9 positive malignancies. In the Phase 1 study, MabVax's MVT-5873, a fully human antibody, was given in combination with nab-paclitaxel and gemcitabine to patients newly diagnosed with CA19-9 positive pancreatic cancer. MVT-5873 at a dose of 0.125 mg/kg when added to first-line chemotherapy was generally well tolerated by all subjects.   The Company reported that all six patients had measurable tumor reductions, with four patients meeting the criteria for partial response (PR) and two patients meeting the criteria for stable disease (SD).

  • ACCESSWIRE2 months ago

    INVESTOR NOTICE: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX

    LOS ANGELES, CA / ACCESSWIRE / February 8, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Therapeutics ...

  • MabVax to Present at BIO CEO & Investor Conference
    PR Newswire2 months ago

    MabVax to Present at BIO CEO & Investor Conference

    SAN DIEGO, Feb. 7, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that David Hansen, MabVax's President and Chief Executive Officer will present at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 11:15 a.m. EST in New York, NY. As part of his presentation, Mr. Hansen will provide a corporate overview, including a clinical update on the Company's two lead clinical development programs: (1) Its fully human antibody therapeutic product, MVT-5873, currently in a Phase 1 clinical study in combination with gemcitabine and nab-paclitaxel in first line therapy for the treatment of newly diagnosed pancreatic cancer patients.

  • MabVax Therapeutics Closes $2.1 Million Private Placement Financing
    PR Newswire2 months ago

    MabVax Therapeutics Closes $2.1 Million Private Placement Financing

    SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (the "Company") (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the closing of a private financing for a total of $2.1 million. The Company entered into separate purchase agreements with accredited investors pursuant to which it agreed to sell an aggregate of $2.1 million worth of shares of common stock, par value $0.01 per share at a purchase price of $0.75 per share (or, at the election of any investor who, as a result of receiving common stock would hold in excess of 4.99% of the Company's issued and outstanding common stock, shares of its newly designated 0% Series M Convertible Preferred Stock) and a three year warrant to purchase shares of common stock equal to 70% of such number of shares of common stock purchased (or, if Series M Preferred Stock, 70% of the shares of common stock issuable upon conversion of the Series M Preferred Stock).

  • ACCESSWIRE3 months ago

    IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Investigation of Securities Claims Against MabVax Therapeutic Holdings, Inc. - MBVX

    LOS ANGELES, CA / ACCESSWIRE / January 31, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Therapeutics ...

  • PR Newswire3 months ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX)

    NEW YORK , Jan. 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MabVax Therapeutics Holdings, Inc. ("MabVax" ...

  • Business Wire3 months ago

    INVESTOR ALERT: Investigation of MabVax Therapeutics Announced by Holzer & Holzer

    Holzer & Holzer, LLC is investigating whether MabVax Therapeutics Holdings, Inc. complied with the federal securities laws. On January 30, 2018, MabVax announced that it received notice that the Securities and Exchange Commission is investigating and examining certain of the Company’s filed registration statements and subsequent amendments. The price of MabVax stock fell significantly following the ...

  • All You Need To Know About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Risks
    Simply Wall St.3 months ago

    All You Need To Know About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) Risks

    If you are a shareholder in MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile ofRead More...

  • Business Wire3 months ago

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against MabVax Therapeutics Holdings, Inc. – MBVX

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of MabVax Therapeutics Holdings, Inc.

  • MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements
    PR Newswire3 months ago

    MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements

    SAN DIEGO, Jan. 30, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it received notice that the Securities and Exchange Commission ("SEC") was conducting an investigation and examination pursuant to Section 8(e) of the Securities Act of 1933, as amended, relating to certain of the Company's registration statements (and amendments thereto). MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer.

  • How Should Investors Feel About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) CEO Pay?
    Simply Wall St.3 months ago

    How Should Investors Feel About MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) CEO Pay?

    John Hansen took the reins as CEO of MabVax Therapeutics Holdings Inc’s (NASDAQ:MBVX) and grew market cap to $18.83M recently. Understanding how CEOs are incentivised to run and grow theirRead More...

  • MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
    PR Newswire3 months ago

    MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update

    SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today provided an update on its business strategy initiatives. In September 2017, MabVax announced its engagement with Greenhill & Co. (GHL) to serve as an advisor to assist the Company in exploring and evaluating strategic options with the goal of maximizing stockholder value. With the assistance of Greenhill, MabVax is currently in advanced discussions with a variety of interested parties for potential multiple transaction proposals as well as continuing to identify new opportunities. In parallel with the strategic initiatives efforts led by Greenhill & Co., MabVax continues to advance its Phase 1 clinical programs including the MVT-1075 radioimmunotherapy clinical trial for the treatment of pancreatic, colon and lung cancers, and the MVT-5873 clinical trial in combination with a standard of care chemotherapy as a first line therapy for patients newly diagnosed with pancreatic cancer.  In addition, the Company's lead research program, HuMab-Tn, has generated significant interest and continues as part of its discussions with external parties.

  • Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?
    Simply Wall St.4 months ago

    Is MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) On The Right Side Of Disruption?

    MabVax Therapeutics Holdings Inc (NASDAQ:MBVX), a USD$14.82M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, suchRead More...

  • ACCESSWIRE4 months ago

    Wired News – MabVax Therapeutics Completes Enrollment and Initial Patient Dosing in Expanded Cohort of the Phase-1 Trial Evaluating MVT-5873

    LONDON, UK / ACCESSWIRE / December 22, 2017 / Active-Investors.com has just released a free research report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX ) ("MabVax"). If you want access ...

  • MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy
    PR Newswire4 months ago

    MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy

    In October, the Company provided an update at the AACR-NCI-EORTC International Conference highlighting encouraging preliminary tumor response data when MVT-5873 was given in combination with nab-paclitaxel and gemcitabine in newly diagnosed patients with CA19-9 positive pancreatic cancer. At this meeting the Company reported that this dose was generally well tolerated in all subjects and that two of three subjects receiving 0.125 mg/kg MVT-5873 in combination with gemcitabine plus nab-paclitaxel had a partial response ("PR"). This portion of the Company's Phase 1 clinical trial is an open-label, multi-center nonrandomized dose escalation study evaluating the safety and maximum tolerated dose ("MTD") and recommended Phase 2 dose of MVT-5873 in combination with a standard of care chemotherapy in subjects with pancreatic and other CA19-9 positive malignancies.